rhodamine 123 in tumour cells with overexpressed pgp-170 was significantly reduced as compared to the MDR antagonist-treated tumour cells (Watt et al, 1990; Chaudhary and Roninson, 1991; Kiehntopf et al, 1994) . The other Paclitaxel resistance type includes TRAG-1-5 (Paclitaxel resistance-associated gene 1-5) (Duan et al, 1997) , p53 expression (Catherine et al, 1995) (Vikhanskaya et al, 1998) , alteration of β-tubulin isoform (Dumontet et al, 1996) , changes in the level of intracellular glutathione (Liebmann et al, 1993) , or cell growth morphology (Frankel et al, 1997) .
Berberine, an alkaloid isolated from Coptis chinese, Hydrastis canadensis L., Berberidaceae, has been found to have antibacterial (Sun et al, 1988) and anti-inflammatory effects. Moreover, the Coptis chinese is frequently utilized in Chinese herbal medicine. The mechanism of berberine-induced growth inhibition in tumour cells is not well understood, but it has been documented that berberine interacts with DNA to form complex (Jenning and Ridler, 1983; Taira et al, 1994) , inhibits DNA, RNA and protein synthesis in sarcoma S180 cells in vitro (Creasey, 1979) . In addition, berberine has also been found to affect cell cycle progression. Berberine-treated HL-60 cells had an increased G2/M phase population (Kuo et al, 1995) . In our previous studies, we have found that berberine decreased α-fetoprotein secretion (Chi et al, 1994) and upregulated pgp-170 expression in hepatoma cells (Lin et al, 1999) .
In this study we examined the role of MDR expression on oral, gastric and colon cancer cells in response to Paclitaxel treatment; we show that berberine up-regulated the MDR1 expression and enhanced the efflux ability of this transporter on six cancer cell lines. In addition, increased MDR1 expression is accompanied with reduction of Paclitaxel-induced cytotoxicity, cell cycle alterations, apoptosis and morphology changes in cancer cells. These School of Medicine, National Yang-Ming University, Taipei, Taiwan, ROC results suggest that MDR1 expression is associated with attenuation of Paclitaxel-induced response.
MATERIALS AND METHODS

Cell culture
Human oral cancer cell lines, OC2 (Wong et al, 1990) and KB (obtained from American Type Culture Collection, ATCC); human gastric carcinoma cell line, SC-M1 (Jin et al, 1987) and human colon cancer cell line, COLO 205 (obtained from ATCC) were cultured in RPMI-1640 (Gibco, Grand Island, NY, USA) medium supplemented with 10% heat-inactivated fetal bovine serum (Hyclone, Logan, UT, USA) and 0.01 mg ml -1 gentamycin (Gibco). A murine colon cell line, CT26, was cultured in Dulbecco's modified Eagles medium (DMEM; Gibco) containing 10% heat-inactivated fetal bovine serum (Hyclone), 0.01 mg ml -1 gentamycin, and 0.1 mM non-essential amino acid. Human gastric carcinoma cell line, NUGC-3 (Sekiguchi et al, 1978) was cultured in RPMI-1640 and DMEM in a 1:1 ratio supplemented with L-glutamine (2 mM; Gibco), kanamycin (100 µg ml -1 ; Gibco) and 10% heat-inactivated fetal bovine serum. The cells were kept in a humidified incubator with 5% carbon dioxide and 95% air at 37°C.
Drug treatment
Berberine (Sigma; B 3251, St Louis, MO, USA) and Paclitaxel (Biomol Research Labs, PA, USA) were dissolved in double distilled water and dimethylsulphoxide (DMSO) respectively. Six cell lines were treated with berberine (0.32-320 µM) for 24 h. For some experiments, cells were pretreated with berberine (32 µM) for 24 h, followed by replacement with fresh medium containing DMSO (0.1%) or various concentrations of Paclitaxel (0.001, 0.01, 0.1, 1, 10 µM) for an additional 24 h. After drug treatment, cells were harvested by TEG (0.125% trypsin, 0.05% EDTA, 0.05 g ml -1 glucose) and used for the following assays.
MDR1 transporter expression
The cell pellet (1 × 10 6 ) was first resuspended in 100 µl phosphatebuffered saline (PBS), followed by incubation with 20 µl (12.5 µg ml -1 ) anti-human MDR1 monoclonal antibody conjugated with phycoerythrin (PE) (Immunotech, UIC2 clone) for 15 min at room temperature. Non-specific binding was determined with an isotype control of mouse PE-conjugated IgG1. After incubation, cells were washed twice with PBS then resuspended in 500 µl PBS for flow cytometic analysis.
Multidrug-resistance protein expression
The cell pellets (1 × 10 6 ) were added with lysing buffer (0.5% Triton X-100, 0.2 µg ml -1 Na 2 EDTA.2H 2 O, and 1% bovine serum albumin in PBS) and left on ice for 15 min. The mixture was then added with 100% methanol pre-cooled to -20°C and centrifuged at 300 g for 5 min. The supernatant was discarded and pellet was washed with PBS again. For primary antibody staining, the cell pellets were incubated with 20 µl mouse anti-MRP monoclonal antibody (1:50 dilution) (Chemicon International Inc., QCRL-3 clone) at 4°C for 30 min. Non-specific binding was determined using mouse IgG2a antibody. The cells were washed with PBS followed by incubation with goat anti-mouse antibody conjugated with fluorescein isothiocyanate (FITC) (1:30 dilution) (Organon Teknika Co.) at room temperature for 30 min. Finally, cells were washed with PBS and the multidrug resistance protein (MRP) expression was examined by flow cytometry.
Functional assay of MDR1 transporter
Previously, it has been reported that the retention of rhodamine 123 correlated well with the function of pgp-170 (Ludescher et al, 1992; Kiehntopf et al, 1994; Petriz and Garcia-Lopez, 1997; Salvioli et al, 1997) . Therefore, retention of rhodamine 123 can be used as an indicator of pgp-170 function. Cells (2-3 × 10 5 ) were treated with 0.32, 3.2, 32, 320 µM berberine for 24 h prior to the addition of 10 µg ml -1 rhodamine 123 (Sigma). After incubation at 37°C for 5 min, cells were harvested and centrifuged at 300 g for 10 min. Cell pellets were resuspended with 500 µl PBS and immediately used for flow cytometic analysis of rhodamine 123 retention.
MTT viability assay
Cells were cultured in 96-well cell culture cluster (Costar) at a density of 4 × 10 4 cells ml -1 . After drug treatment for 24-72 h, medium was discarded and replaced with an equal volume (100 µl) of fresh medium containing MTT (0.456 mg ml -1 ; 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide) for incubation 1.5 h in a 37°C incubator. The medium was discarded and then 100 µl DMSO were added. Cell viability was determined according to the colourimetric comparison by reading OD values 
Flow cytometric analysis of DNA content
The cell pellets (1 × 10 6 ) were added with lysing buffer (0.5% Triton X-100, 0.2 µg ml -1 Na 2 EDTA.2H 2 O and 1% bovine serum albumin in PBS) and left on ice for 15 min. The mixture was then added with 100% methanol pre-cooled to -20°C and centrifuged at 300 g for 5 min. The supernatant was discarded and pellet was washed with PBS again. The pellet was stained with DNA staining solution (50 µg ml -1 -propidium iodide, 5 k units ml -1 of RNaseA for 30 min at 4°C in the dark. The DNA content of each cell was measured using a Becton Dickinson FACSCalibur flow cytometer.
Flow cytometry
Cells (10 000) were analysed on a Becton Dickinson FACSCalibur flow cytometer using an argon-ion laser (15 mWatt) with incident beam at 488 nm. Green fluorescence (rhodamine 123 or FITC) corresponding to efflux ability of MDR1 transporter or MRP expression were collected through a 530 nm filter, while the red fluorescence (PE) representing either the level of MDR1 transporter or DNA content (propidium iodide) was collected through a 585 nm filter. Data were acquired and analysed using FACS/CellQuest software on a Power Macintosh 7600/120 computer. Apoptotic cells and cells at specific cycle phases were determined by ModFit LT software.
Morphology changes
To observe the cell morphology, OC2 and SC-M1 cells (2 ϫ 10 6 cells) were cultured on 75 cm 2 cell culture flasks (Corning) and treated with various doses of the drug. Photograph was taken at 300-fold magnification on an inverted phase-contrast microscope (Olympus; IMT-2)
Statistical analysis
Statistical anslyses were performed using the Sigmastat software. Comparisons between the means of various treatment groups were analysed using Student's t-test or ANOVA. Tukey test was used for multiple comparisons. The difference was considered significant when P < 0.05. Figure 1 shows the pgp-170 expression on berberine-treated six different cancer cell lines (OC2, KB, SC-M1, NUGC-3, CT26 and COLO 205). The expression of pgp-170 was increased significantly in five cell lines (OC2, KB, SC-M1, NUGC-3, COLO 205) after treatment with 32 µM berberine. No specific binding of pgp-170 was observed using isotype antibody. The expression of pgp-170 in CT26 cells was much less than the other five cell lines. When the berberine dose is increased to 160 µM or 320 µM, a further increase of pgp-170 expression was observed on OC2 and CT26 cells respectively. In comparison, no further increase in levels of pgp-170 was found on 160 µM berberine-treated KB, SC-M1, NUGC-3 and COLO 205 cells. Table 1 shows that 0.32 and 3.2 µM of berberine had little effect on cell viability. The viability of OC2, SC-M1 and COLO 205 cells decreased to 72.3-75.2% of control 24 h after a 32 µM berberine treatment. When the dose of berberine is increased to 320 µM, the viability further reduced to 17.8-34.4% of control. Since treatment of cells with 32 µM of berberine resulted in maximal expression of pgp-170 without significant effect on cell viability, we used 32 µM berberine treatment for further analyses. It had been documented that the efflux of rhodamine 123 correlated well with pgp-170 expression. By this rationale, we used rhodamine 123 to evaluate whether the pgp-170 that expressed on cancer cells is functional. Figure 2 shows that two oral cancer cell lines (OC2, KB) had similar pattern of berberine-induced response. The efflux of rhodamine 123 showed a decreasing trend with the elevated dose of berberine. The efflux of rhodamine 123 in two gastric cancer cell lines (SC-M1, NUGC-3) and a colon cancer cell line (COLO 205) after 32 µM berberine treatment decreased significantly (P < 0.05) as compared with medium control. No significant decrease in rhodamine 123 retention was observed in berberine-treated CT26 cells. This corresponded well with our observation (Figure 1 ) that the pgp-170 expression was not increased in CT26 cells after a 32 µM berberine treatment.
RESULTS
In order to understand whether the enhanced efflux of pgp-170 correlates with drug resistance, we further investigated the effect of berberine treatment on Paclitaxel-induced response in three cell lines. Figure 3 shows that no significant decrease in viability of OC2, and SC-M1 cells was observed after Paclitaxel treatment for 24 h. The viability of COLO 205 cells showed a significant decrease (P < 0.001) after treatment with 10 nM-10 µM Paclitaxel for 24 h. No significant difference in viability was observed in cells treated with Paclitaxel alone and cells pretreated with berberine then treated with Paclitaxel (P > 0.05). When cancer cells were treated with 10 nM-10 µM Paclitaxel for 72 h, significant (P < 0.05) decreases in viability were observed in three cancer cell lines. Significantly higher viabilities (P < 0.05) were observed in berberine pretreatment groups than Paclitaxel (0.01-10 µM) treatment groups.
Previously, we had reported that low (10 nM) dose of Paclitaxel induced early apoptosis of SC-M1 cells while high (100 nM) dose Paclitaxel induced G2/M phase arrest prior to cell death (Chang et al, 1996) . In order to determine whether berberine pretreatment affected Paclitaxel-induced cycle changes in cancer cells, cells were pretreated with berberine (32 µM) for 24 h followed by treatment with fresh medium containing low (10 nM) or high (100 nM) dose of Paclitaxel. Figure 4 shows that the DNA histogram of OC2 cells treated with berberine for 24 h (B 24, BW) had no remarkable alteration as compared with medium control (C24, C48). Low and high dose Paclitaxel treatment of OC2 cells resulted in apoptotic peaks and G2/M arrest respectively. In comparison, there were no significant changes on cell cycle in low (BL) or high (BH) dose Paclitaxel treatment of berberine-pretreated OC2 cells, as compared to vehicle controls (BD, BW). In SC-M1 cells, berberine treatment had no effect on cell cycle progression while low and high dose Paclitaxel treatment resulted in an apoptotic peak and a G2/M phase arrested cell population. These results were in accordance with our previous findings. However, it is interesting that pretreatment with berberine blocked the Paclitaxelinduced changes in cell cycle progression. No significant apoptosis and G2/M arrest was observed on low (BL) or high dose (BH) Paclitaxel treatment groups. For COLO 205 cells, high dose Paclitaxel treatment induced a significant G2/M phase arrest while low dose Paclitaxel treatment has no significant effect on cell cycle progression. Similarly, the Paclitaxel-induced cell cycle effect was blocked by berberine-pretreatment. Figure 5 shows the effect of berberine on Paclitaxel-induced changes on morphology of OC2 (A-F) and SC-M1 cells (G-L). Low (10 nM) or high (100 nM) dose of Paclitaxel induced OC2 cells to round up or produce membrane blebbing. Similar morphological alterations were found on high (100 nM) dose Paclitaxeltreated SC-M1 cells. Berberine (32 µM) pretreatment for 24 h had no significant effect on both OC2 ( Figure 5D ) and SC-M1 cells ( Figure 5J ). In addition, pretreatment of OC2 and SC-M1 cells with berberine completely blocked the low or high dose Paclitaxel induced morphological changes.
In order to investigate whether MRP expression is also involved in berberine-induced effect, we further examined the MRP expression in six cancer cell lines treated with berberine for 24 h. A slight increase in the MRP expression was observed in berberine-treated cells. Figure 6 shows that a 32 µM berberine treatment for 24 h slightly increased the expression of MRP in OC2, SC-M1 and COLO 205 cell lines.
DISCUSSION
Berberine had been documented to inhibit RNA, protein synthesis and integrate into DNA to form complex. Previously, synergistic cytotoxic effect of berberine (400 µM) and BCNU was found in brain tumour cells (Zhang et al, 1990) , whether berberine has synergistic or antagonistic effect with other chemotherapeutic drug is not clear.
In this study, we have found that the cell growth of berberine (32 µM)-treated OC2, SC-M1 and COLO 205 cells was about 75% of medium control (Table 1) . Berberine not only induced pgp-170 expression on six cancer cell lines (Figure 1) but also elevated the function of pgp-170 in these cancer cell lines (Figure 2 ). Nishino et al had found that berberine inhibited the effect of 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced responses (Nishino et al, 1986) . In another study, the accumulation of TPA and TPA-induced protein kinase C activity in MDR-expressed KB cells are slightly less than the MDR-negative KB cells (Cloud-Heflin et al, 1996) . The decreased TPA-induced responses may be due to, at least in part, efflux of TPA by MDR transporter. Taken together, it seems reasonable to conclude that berberine may have modulated MDR1 expression and leads to reduced drug uptake in tumour cells. Although the mechanism underlying berberine elevated pgp-170 expression is unclear but some reports indicated that cycloheximide-induced protein synthesis inhibition elevated pgp-170 mRNA expression in HepG2 cells (Gant et al, 1992; Schuetz et al, 1995) . The cycloheximide-induced polysome stabilization may have contributed to the elevation of pgp-170 mRNA expression. Berberine has been reported to inhibit protein synthesis in sarcoma 180 cells (Creasey, 1979) , whether berberine stabilized polysome and increased pgp-170 mRNA in these cancer cells is worthy of further investigation.
In order to evaluate whether berberine-modulated pgp-170 function can interfere with chemotherapeutic drug response in tumour cells, we assessed the Paclitaxel effect on cancer cells pretreated with berberine. Berberine decreased Paclitaxel-induced cytotoxicity in OC2, SC-M1, COLO 205 cells (Figure 3) . In addition, berberine blocked high (0.1 µM) dose Paclitaxel-induced cell cycle arrest at G2/M phase in OC2, SC-M1, COLO 205 and abrogated low (0.01 µM) dose Paclitaxel-elicited sub-G0/G1 apoptosis in OC2, SC-M1 cells (Figure 4) . Many studies documented that combination of some chemotherapeutic drugs with Paclitaxel decreased the response of Paclitaxel (Akutsu et al, 1995; Kano et al, 1996a Kano et al, , 1996b . Most of these drugs arrested tumour cells at S phase and the reduction of cells at G0/G1 or G2/M phases most likely contributed to reduced responses to Paclitaxel. In a previous study, we had reported that low dose of Paclitaxel induced apoptosis in gastric cancer cells (Chang et al, 1996) and this effect is cycle-dependent (Lin et al, 1998) . It is interesting that similar effect was observed in OC2 cells. Berberine-induced cell cycle arrest at G2/M phase and apoptosis in Balb/c 3T3 cells (Yang et al, 1996) , however, the dose of berberine used (268-537 µM) was much higher than we used (32 µM) in this study. In this study, berberine treatment did not induce G2/M arrest and berberine attenuated Paclitaxel-induced response was not the result of berberine-elicited cycle arrest effect (Figure 4) .
Clinically, the phase II clinical trial of Paclitaxel had been performed on patients with oesophagus, gastric, hepatic or colon cancer (Rowinsky et al, 1992; Einzig et al, 1993; Ajani et al, 1994; Chao et al, 1998 ). The response rates were dependent upon cancer types and administered drug concentration, but many reports indicated that the low response rates were possibly associated with MDR1 expression. In this study, we have found that berberine upregulated MDR1 expression in tumour cells (Figure 1 ) and the pgp-170 was functional (Figure 2 ). Most importantly, pretreatment of cancer cells with berberine blocked Paclitaxel-induced responses (Figures 3-5) . These results suggest that MDR1 may be involved in low response rates of Paclitaxel. At present, no information is available on clinical combination of berberine and chemotherapeutic agents for treatment of cancer patients. However, it is worthy to point out that for patients receiving chemotherapy and simultaneously taking Chinese herbal medicine containing berberine, reduced therapeutic effect may result from up-regulation of MDR1.
Recently, another member of ABC family, MRP, had been found with high levels of MRP1, cMOAT, MRP3 or MRP5 expression in stomach, liver, colon or salivary gland respectively (Kool et al, 1997) . In this study, we have found that berberine treatment slightly enhanced MRP expression in OC2, SC-M1 and COLO 205 cancer cells (Figure 6 ). It seems that the contribution of this slightly increased MRP in reduction of rhodamine 123 retention may be limited. Nevertheless, our results are the first to point out that there is antagonistic action between Paclitaxel and berberine mediated, at least in part, by MDR1 expression. 
